Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2017, Article ID 6136914, 5 pages
https://doi.org/10.1155/2017/6136914
Case Report

Distressing Visual Hallucinations after Treatment with Trazodone

Hospital de Magalhães Lemos, Porto, Portugal

Correspondence should be addressed to Gustavo Santos; moc.liamg@88leugimovatsug

Received 30 April 2017; Accepted 23 May 2017; Published 18 June 2017

Academic Editor: Yasuhiro Kaneda

Copyright © 2017 Gustavo Santos and Ana Maria Moreira. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Wilson, D. J. Nutt, C. Alford et al., “British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders,” Journal of Psychopharmacology, vol. 24, no. 11, pp. 1577–1601, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Tylor, C. Paton, and S. Kapur, Eds., The Maudsley Prescribing Guidelines in Psychiatry, Wiley-Blackwell, Chichester, UK, 11th edition, 2012.
  3. R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery, “Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety,” Drugs, vol. 21, no. 6, pp. 401–429, 1981. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Haria, A. Fitton, and D. McTavish, “Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders,” Drugs and Aging, vol. 4, no. 4, pp. 331–355, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Bossini, I. Casolaro, D. Koukouna, F. Cecchini, and A. Fagiolini, “Off-label uses of trazodone: a review,” Expert Opinion on Pharmacotherapy, vol. 13, no. 12, pp. 1707–1717, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Collerton and J. Taylor, “Advances in the treatment of visual hallucinations in neurodegenerative diseases,” Future Neurology, vol. 8, no. 4, pp. 433–444, 2013. View at Publisher · View at Google Scholar
  7. L. Burghaus, C. Eggers, L. Timmermann, G. R. Fink, and N. J. Diederich, “Hallucinations in neurodegenerative diseases,” CNS Neuroscience and Therapeutics, vol. 18, no. 2, pp. 149–159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Bertram and D. R. Williams, “Visual hallucinations in the differential diagnosis of parkinsonism: table 1,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 83, no. 4, pp. 448–452, 2012. View at Publisher · View at Google Scholar
  9. R. C. Teeple, J. P. Caplan, and T. A. Stern, “Visual hallucinations: differential diagnosis and treatment,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 11, no. 1, pp. 26–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. B. W. Rovner, “The charles bonnet syndrome: a review of recent research,” Current Opinion in Ophthalmology, vol. 17, no. 3, pp. 275–277, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Bernardin, R. Schwan, L. Lalanne et al., “The role of the retina in visual hallucinations: a review of the literature and implications for psychosis,” Neuropsychologia, vol. 99, pp. 128–138, 2017. View at Publisher · View at Google Scholar
  12. L. D. Kartsounis, M. James-Galton, and G. T. Plant, “Anton syndrome, with vivid visual hallucinations, associated with radiation induced leucoencephalopathy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 8, pp. 937-938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. C. P. Panayiotopoulos, “Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 66, no. 4, pp. 536–540, 1999. View at Publisher · View at Google Scholar
  14. M. Bloechliger, A. Ceschi, S. Rüegg et al., “Risk of seizures associated with antidepressant use in patients with depressive disorder: follow-up study with a nested case—control analysis using the clinical practice research Datalink,” Drug Safety, vol. 39, no. 4, pp. 307–321, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. C. R. Hepworth, K. Ashcroft, and D. Kingdon, “Auditory hallucinations: a comparison of beliefs about voices in individuals with schizophrenia and borderline personality disorder,” Clinical Psychology and Psychotherapy, vol. 20, no. 3, pp. 239–245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Sheaves, P. E. Bebbington, G. M. Goodwin et al., “Insomnia and hallucinations in the general population: findings from the 2000 and 2007 British psychiatric morbidity surveys,” Psychiatry Research, vol. 241, pp. 141–146, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Waters, D. Collerton, D. H. ffytche et al., “Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease,” Schizophrenia Bulletin, vol. 40, supplement 4, pp. S233–S245, 2014. View at Publisher · View at Google Scholar
  18. J. E. Maglione, S. E. Thomas, and D. V. Jeste, “Late-onset schizophrenia: do recent studies support categorizing los as a subtype of schizophrenia?” Current Opinion in Psychiatry, vol. 27, no. 3, pp. 173–178, 2014. View at Google Scholar
  19. C. Baethge, R. J. Baldessarini, K. Freudenthal, A. Streeruwitz, M. Bauer, and T. Bschor, “Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia,” Bipolar Disorders, vol. 7, no. 2, pp. 136–145, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Paparelli, M. Di Forti, P. D. Morrison, and R. M. Murray, “Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light,” Frontiers in Behavioral Neuroscience, vol. 5, 2011, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024828/. View at Publisher · View at Google Scholar
  21. R. Patel, P. Reiss, H. Shetty et al., “Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study,” British Medical Journal, vol. 5, no. 12, Article ID e008341, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Grosset and D. G. Grosset, “Prescribed drugs and neurological complications,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 75, supplement 3, pp. iii2–iii8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Young and S. K. Inouye, “Delirium in older people,” The British Medical Journal, vol. 334, no. 7598, pp. 842–846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Stahl, “Mechanism of action of trazodone: a multifunctional drug,” CNS Spectrums, vol. 14, no. 10, pp. 536–546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Celada, M. V. Puig, M. Amargós-Bosch, A. Adell, and F. Artigas, “The therapeutic role of 5-HT1A and 5-HT2A receptors in depression,” Journal of Psychiatry and Neuroscience, vol. 29, no. 4, pp. 252–265, 2004. View at Google Scholar
  26. A. Gobert and M. J. Millan, “Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats,” Neuropharmacology, vol. 38, no. 2, pp. 315–317, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. J. J. Balsara, S. A. Jadhav, R. K. Gaonkar, R. V. Gaikwad, and J. H. Jadhav, “Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats,” Psychopharmacology, vol. 179, no. 3, pp. 597–605, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. O. D. Howes and S. Kapur, “The dopamine hypothesis of schizophrenia: version III—the final common pathway,” Schizophrenia Bulletin, vol. 35, no. 3, pp. 549–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. W. B. Mendelson, “A review of the evidence for the efficacy and safety of Trazodone in Insomnia,” The Journal of Clinical Psychiatry, vol. 66, no. 04, pp. 469–476, 2005. View at Publisher · View at Google Scholar
  30. K. Ruxton, R. J. Woodman, and A. A. Mangoni, “Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis,” British Journal of Clinical Pharmacology, vol. 80, no. 2, pp. 209–220, 2015. View at Publisher · View at Google Scholar
  31. I. Cancelli, G. Marcon, and M. Balestrieri, “Factors associated with complex visual hallucinations during antidepressant treatment,” Human Psychopharmacology, vol. 19, no. 8, pp. 577–584, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. P. Popli, M. A. Fuller, and G. E. Jaskiw, “Sertraline and psychotic symptoms: a case series,” Annals of Clinical Psychiatry, vol. 9, no. 1, pp. 15–17, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Tomita, N. Yasui-Furukori, and S. Kaneko, “Visual hallucinations during duloxetine treatment in a patient with major depressive disorder,” Clinical Neuropharmacology, vol. 36, no. 5, pp. 175-176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. V. F. Capaldi and R. B. Carr, “Citalopram-induced hallucinations and delusions in a young adult,” General Hospital Psychiatry, vol. 32, no. 6, pp. 648.e1–648.e3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Yasui-Furukori and S. Kaneko, “Hallucination induced by paroxetine discontinuation in patients with major depressive disorders,” Psychiatry and Clinical Neurosciences, vol. 65, no. 4, pp. 384-385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Rolland, R. Jardri, A. Amad, P. Thomas, O. Cottencin, and R. Bordet, “Pharmacology of hallucinations: several mechanisms for one single symptom?” BioMed Research International, vol. 2014, Article ID 307106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Markel, A. Lee, R. D. Holmes, and E. F. Domino, “LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents,” The Journal of Pediatrics, vol. 125, no. 5, part 1, pp. 817–819, 1994. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Goldman, D. Galarneau, and R. Friedman, “New onset LSD flashback syndrome triggered by the initiation of SSRIs,” Ochsner Journal, vol. 7, no. 1, pp. 37–39, 2007. View at Google Scholar · View at Scopus
  39. I. Shiotsuki, T. Terao, N. Ishii, and K. Hatano, “Auditory hallucinations induced by trazodone,” British Medical Journal, Case Reports, vol. 2014, 2014, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987616/. View at Google Scholar
  40. Y. Mizoguchi and A. Monji, “Low-dose-trazodone-induced disorganized type psychosis,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 17, no. 2, pp. 253-254, 2005. View at Publisher · View at Google Scholar · View at Scopus